ClariTrial | Search Clinical Trials

Explore/cardiovascular heart disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

579 results for “cardiovascular heart disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 39

Recruiting

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus (Sle)

Nicotinamide Riboside

National Heart, Lung, and Blood Institute (NHLBI)78 participants1 site · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction

Phase 3Coronary Artery DiseaseAcute Myocardial Infarction (AMI)Coronary Atherosclerosis of Native Coronary Artery

ZiltivekimabPlacebo

ECRI bv332 participants1 site · SwitzerlandCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients

Phase 2Breast CancerMetastatic Breast CancerCancer Therapy-Related Cardiac Dysfunction

Nicotinamide RibosidePlacebo

University Hospital, Akershus60 participants1 site · NorwayCompletes Aug 2025

Compare CT.gov Full analysis →

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes May 2030

Compare CT.gov Full analysis →

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Phase 3Atrial Fibrillation (AF)

AbelacimabPlacebo

Anthos Therapeutics, Inc.1,900 participants734 sites · United States, Argentina, BrazilCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

Phase 2Cardiovascular Autonomic NeuropathyType 2 DiabetesDiabetic Neuropathies

Kerendia (Finerenone, BAY94-8862)Placebo

Peter Rossing100 participants2 sites · DenmarkCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

Phase 2Atrial FibrillationEsophageal Carcinoma

Amiodarone HydrochlorideSaline

OHSU Knight Cancer Institute90 participants1 site · United StatesCompletes Aug 2027

Compare CT.gov Full analysis →

Recruiting

Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts

Phase 2HLH - Hypoplastic Left Heart SyndromeDORVDILV - Double Inlet Left Ventricle

Tissue Engineered Vascular Grafts

Nationwide Children's Hospital24 participants1 site · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

Phase 3Atrial Fibrillation

AFSW Guided DOACContinuous DOAC therapy

Johns Hopkins University5,350 participants93 sites · United StatesCompletes Jul 2029

Compare CT.gov Full analysis →

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Phase 3Plasma Cell MyelomaRISS Stage I Plasma Cell MyelomaRISS Stage II Plasma Cell Myeloma

BortezomibDaratumumab and Hyaluronidase-fihjDexamethasone+2 more

ECOG-ACRIN Cancer Research Group1,450 participants649 sites · United States, Puerto RicoCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Bioenergetic Effect of Pioglitazone in CLD-PH

Phase 2Pulmonary HypertensionPulmonary Hypertension Due to Lung Diseases

Pioglitazone 30mgPlaceboLabs

Emory University20 participants1 site · United StatesCompletes Feb 2028

Compare CT.gov Full analysis →

Recruiting

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT

Phase 2Iliofemoral; Thrombosis

Perivascular dexamethasonePerivascular sham

Mercator MedSystems, Inc.60 participants15 sites · United States, Ireland, United KingdomCompletes May 2025

Compare CT.gov Full analysis →

Recruiting

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Phase 2Systemic SclerosisDiffuse Sclerosis SystemicInterstitial Lung Disease

CyclophosphamideMesnaRituximab+6 more

Paul Szabolcs8 participants3 sites · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Phase 2Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension, Interstitial Lung Disease

ROC-101

AllRock Bio, Inc.40 participants19 sites · United States, Australia, CanadaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Phase 2Heart AttackEnlarged Heart

SGLT-2 inhibitorsPlacebo

Minneapolis Heart Institute Foundation81 participants1 site · United StatesCompletes Dec 2028

Compare CT.gov Full analysis →

1–15 of 579

Explore/cardiovascular heart disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

579 results for “cardiovascular heart disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 39

Recruiting

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus (Sle)

Nicotinamide Riboside

National Heart, Lung, and Blood Institute (NHLBI)78 participants1 site · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction

Phase 3Coronary Artery DiseaseAcute Myocardial Infarction (AMI)Coronary Atherosclerosis of Native Coronary Artery

ZiltivekimabPlacebo

ECRI bv332 participants1 site · SwitzerlandCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients

Phase 2Breast CancerMetastatic Breast CancerCancer Therapy-Related Cardiac Dysfunction

Nicotinamide RibosidePlacebo

University Hospital, Akershus60 participants1 site · NorwayCompletes Aug 2025

Compare CT.gov Full analysis →

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes May 2030

Compare CT.gov Full analysis →

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Phase 3Atrial Fibrillation (AF)

AbelacimabPlacebo

Anthos Therapeutics, Inc.1,900 participants734 sites · United States, Argentina, BrazilCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

Phase 2Cardiovascular Autonomic NeuropathyType 2 DiabetesDiabetic Neuropathies

Kerendia (Finerenone, BAY94-8862)Placebo

Peter Rossing100 participants2 sites · DenmarkCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

Phase 2Atrial FibrillationEsophageal Carcinoma

Amiodarone HydrochlorideSaline

OHSU Knight Cancer Institute90 participants1 site · United StatesCompletes Aug 2027

Compare CT.gov Full analysis →

Recruiting

Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts

Phase 2HLH - Hypoplastic Left Heart SyndromeDORVDILV - Double Inlet Left Ventricle

Tissue Engineered Vascular Grafts

Nationwide Children's Hospital24 participants1 site · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

Phase 3Atrial Fibrillation

AFSW Guided DOACContinuous DOAC therapy

Johns Hopkins University5,350 participants93 sites · United StatesCompletes Jul 2029

Compare CT.gov Full analysis →

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Phase 3Plasma Cell MyelomaRISS Stage I Plasma Cell MyelomaRISS Stage II Plasma Cell Myeloma

BortezomibDaratumumab and Hyaluronidase-fihjDexamethasone+2 more

ECOG-ACRIN Cancer Research Group1,450 participants649 sites · United States, Puerto RicoCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Bioenergetic Effect of Pioglitazone in CLD-PH

Phase 2Pulmonary HypertensionPulmonary Hypertension Due to Lung Diseases

Pioglitazone 30mgPlaceboLabs

Emory University20 participants1 site · United StatesCompletes Feb 2028

Compare CT.gov Full analysis →

Recruiting

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT

Phase 2Iliofemoral; Thrombosis

Perivascular dexamethasonePerivascular sham

Mercator MedSystems, Inc.60 participants15 sites · United States, Ireland, United KingdomCompletes May 2025

Compare CT.gov Full analysis →

Recruiting

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Phase 2Systemic SclerosisDiffuse Sclerosis SystemicInterstitial Lung Disease

CyclophosphamideMesnaRituximab+6 more

Paul Szabolcs8 participants3 sites · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Phase 2Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension, Interstitial Lung Disease

ROC-101

AllRock Bio, Inc.40 participants19 sites · United States, Australia, CanadaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Phase 2Heart AttackEnlarged Heart

SGLT-2 inhibitorsPlacebo

Minneapolis Heart Institute Foundation81 participants1 site · United StatesCompletes Dec 2028

Compare CT.gov Full analysis →

1–15 of 579